Therapeutics for cognitive aging

Annals of the New York Academy of Sciences

Volumn 1191, Issue SUPPL. 1, 2010, Pages E1-E15

  Shineman, Diana W ^a   Salthouse, Timothy A ^b   Launer, Lenore J ^c   Hof, Patrick R ^d   Bartzokis, George ^e   Kleiman, Robin ^f   Luine, Victoria ^g   Buccafusco, Jerry J ^h   Small, Gary W ^e   Aisen, Paul S ⁱ   Lowe, David A ^j   Fillit, Howard M ^a  

^a Alzheimers Drug Discovery Foundation   (United States)

^b UNIVERSITY OF VIRGINIA   (United States)

^c NATIONAL INSTITUTE ON AGING   (United States)

^d MOUNT SINAI SCHOOL OF MEDICINE   (United States)

^e UNIVERSITY OF CALIFORNIA   (United States)

^f PFIZER GLOBAL RESEARCH AND DEVELOPMENT   (United States)

^g CITY UNIVERSITY OF NEW YORK   (United States)

^h MEDICAL COLLEGE OF GEORGIA   (United States)

ⁱ UNIVERSITY OF CALIFORNIA   (United States)

^j Memory Pharmaceutical Corporation   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

AMYLOID BETA PROTEIN[1-42]; CYCLIC NUCLEOTIDE; DONEPEZIL; GALANTAMINE; PITTSBURGH COMPOUND B; RIVASTIGMINE; BIOLOGICAL MARKER;

AGING; ALZHEIMER DISEASE; AMNESIA; CAUDATE NUCLEUS; CHRONIC STRESS; COGNITION; COGNITIVE DEFECT; COMORBIDITY; DEGENERATIVE DISEASE; DEMENTIA; DISEASE MARKER; ENTORHINAL CORTEX; HIPPOCAMPUS; HUMAN; MYELINATION; NEOCORTEX; NERVE CELL; NEUROFIBRILLARY TANGLE; NONHUMAN; POSITRON EMISSION TOMOGRAPHY; PUTAMEN; PYRAMIDAL NERVE CELL; REVIEW; SIGNAL TRANSDUCTION; TEMPORAL CORTEX; BRAIN LEVEL; CLINICAL TRIAL; CONFERENCE PAPER; METABOLISM; MYELIN SHEATH; NEUROSECRETION; PATHOLOGY; PATHOPHYSIOLOGY; PHYSIOLOGY; RISK FACTOR;

AGING; BIOLOGICAL MARKERS; BRAIN CHEMISTRY; CLINICAL TRIALS AS TOPIC; COGNITION; COGNITION DISORDERS; COMORBIDITY; HUMANS; MYELIN SHEATH; NEURONS; NEUROSECRETORY SYSTEMS; RISK FACTORS;

EID: 77952300518     PISSN: 00778923     EISSN: 17496632     Source Type: Book Series    
DOI: 10.1111/j.1749-6632.2010.05532.x     Document Type: Review

References (50)

1. Fillit, H., D.T. Nash, T. Rundek & A. Zuckerman. 2008. Cardiovascular risk factors and dementia. Am. J. Geriatr. Pharmacother. 6: 100-118.
2. Salthouse, T.A. 2010. Major Issues in Cognitive Aging. Oxford University Press. New York.
3. Salthouse, T.A. 2004.What and when of cognitive aging. Current Directions in Psychological Science 13: 140-144.
4. Launer, L.J. 2005. The epidemiologic study of dementia: a life-long quest? Neurobiol. Aging 26: 335-340.
5. Launer, L.J. 2006. Prevention of AD: the which, when, and onwhom?AlzheimerDis. Assoc.Disord. 20: S75-S78.
6. Luine, V.N. 2008. Sex steroids and cognitive function. J. Neuroendocrinol. 20: 866-872.
7. Wallace, M., M. Frankfurt, A. Arellanos, et al. 2007. Impaired recognition memory and decreased prefrontal cortex spine density in aged female rats. Ann. N. Y. Acad. Sci. 1097: 54-57.
8. Luine, V.N., K.D. Beck, R.E. Bowman, et al. 2007. Chronic stress and neural function: accounting for sex and age. J. Neuroendocrinol. 19: 743-751.
9. Bowman, R.E., N.J.Maclusky, S.E.Diaz, et al. 2006.Aged rats: sex differences and responses to chronic stress. BrainRes. 1126: 156-166.
10. Macbeth, A.H., H.E. Scharfman, N.J. Maclusky, et al. 2008. Effects of multiparity on recognition memory, monoaminergic neurotransmitters, and brain-derived neurotrophic factor (BDNF). Horm. Behav. 54: 7-17.
11. Dickstein, D.L., D. Kabaso, A.B. Rocher, et al. 2007. Changes in the structural complexity of the aged brain. Aging Cell 6: 275-284.
12. Hof, P.R. & J.H. Morrison. 2004. The aging brain: morphomolecular senescence of cortical circuits. TrendsNeurosci. 27: 607-613.
13. Morrison, J.H. & P.R. Hof. 1997. Life and death of neurons in the aging brain. Science 278: 412-419.
14. Hof, P.R., K. Cox & J.H. Morrison. 1990. Quantitative analysis of a vulnerable subset of pyramidal neurons in Alzheimer's disease: I. Superior frontal and inferior temporal cortex. J. Comp. Neurol. 301: 44-54.
15. Hof, P.R. & J.H.Morrison. 1990. Quantitative analysis of a vulnerable subset of pyramidal neurons in Alzheimer's disease: II. Primary and secondary visual cortex. J.Comp. Neurol. 301: 55-64.
16. Bussiere, T., G. Gold, E. Kovari, et al. 2003. Stereologic analysis of neurofibrillary tangle formation in prefrontal cortex area 9 in aging and Alzheimer's disease. Neuroscience 117: 577-592.
17. Bussiere, T., P. Giannakopoulos, C. Bouras, et al. 2003. Progressive degeneration of nonphosphorylated neurofilament protein-enriched pyramidal neurons predicts cognitive impairment in Alzheimer's disease: stereologic analysis of prefrontal cortex area 9. J. Comp. Neurol. 463: 281-302.
18. Akram, A., D. Christoffel, A.B. Rocher, et al. 2008. Stereologic estimates of total spinophilin-immunoreactive spine number in area 9 and the CA1 field: relationship with the progression of Alzheimer's disease. Neurobiol. Aging 29: 1296-1307.
19. Gazzaley,A.H.,M.M.Thakker, P.R.Hof&J.H.Morrison. 1997. Preserved number of entorhinal cortex Layer II neurons in agedmacaque monkeys.Neurobiol. Aging 18: 549-553.
20. Duan, H., S.L. Wearne, A.B. Rocher, et al. 2003. Agerelated dendritic and spine changes in corticocortically projecting neurons in macaque monkeys. Cereb. Cortex 13: 950-961.
21. Kabaso,D., P.J. Coskren, B.I.Henry, et al. 2009. The electrotonic structure of pyramidal neurons contributing to prefrontal cortical circuits in macaque monkeys is significantly altered in aging. Cereb. Cortex 19: 2248-2268.
22. Bartzokis, G. 2009. Alzheimer's disease as homeostatic responses to age-related myelin breakdown. Neurobiol. Aging. Epub ahead of print.
23. Duyckaerts, C., B. Delatour &M.C. Potier. 2009. Classification and basic pathology of Alzheimer disease. Acta Neuropathol. 118: 5-36.
24. Price, J.L., A.I. Ko, M.J.Wade, et al. 2001. Neuron number in the entorhinal cortex and CA1 in preclinical Alzheimer disease. Arch. Neurol. 58: 1395-1402.
25. Kochunov, P., T. Coyle, J. Lancaster, et al. 2010. Processing speed is correlatedwith cerebral health markers in the frontal lobes as quantified by neuroimaging.Neuroimage 49: 1190-1199.
26. Bartzokis, G., P.H. Lu & J. Mintz. 2007. Human brain myelination and amyloid beta deposition in Alzheimer's disease. Alzheimers Dement. 3: 122-125.
27. Jack, C.R. Jr., V.J. Lowe, S.D. Weigand, et al. 2009. Serial PIB and MRI in normal, mild cognitive impairment and Alzheimer's disease: implications for sequence of pathological events in Alzheimer's disease. Brain 132: 1355-1365.
28. Ringman, J.M., J. O'Neill,D. Geschwind, et al. 2007. Diffusion tensor imaging in preclinical and presymptomatic carriers of familial Alzheimer's disease mutations. Brain 130: 1767-1776.
29. Bartzokis, G., P.H. Lu, D.H. Geschwind, et al. 2006. Apolipoprotein E genotype and age-related myelin breakdown in healthy individuals: implications for cognitive decline and dementia. Arch. Gen. Psychiatry 63: 63-72.
30. Caselli, R.J., A.C. Dueck, D. Osborne, et al. 2009. Longitudinal modeling of age-related memory decline and the APOE epsilon4 effect. N. Engl. J. Med. 361: 255-263.
31. Small, G.W., S.Y. Bookheimer, P.M. Thompson, et al. 2008. Current and future uses of neuroimaging for cognitively impaired patients. Lancet Neurol. 7: 161-172.
32. Small, G.W., V. Kepe, L.M. Ercoli, et al. 2006. PET of brain amyloid and tau in mild cognitive impairment. N. Engl. J. Med. 355: 2652-2663.
33. Kepe, V., B. Ghetti, M.R. Farlow, et al. 2009. PET of Brain Prion Protein Amyloid in Gerstmann-Straussler- Scheinker Disease. Brain Pathol. Epub ahead of print.
34. Protas, H.D., S.C. Huang, V. Kepe, et al. 2010. FDDNP binding using MR derived cortical surface maps. Neuroimage 49: 240-248.
35. Tolboom, N., W.M. Van Der Flier, M. Yaqub, et al. 2009.Relationship of cerebrospinalfluidmarkers to 11CPiB and 18F-FDDNP binding. J. Nucl. Med. 50: 1464-1470.
36. Buccafusco, J.J., J.W. Beach & A.V. Terry Jr. 2009. Desensitization of nicotinic acetylcholine receptors as a strategy for drug development. J. Pharmacol. Exp. Ther. 328: 364-370.
37. Sood, A.,B.J.Warren, S.J.Webster, et al. 2007. The effects of JWB1-84-1 on memory-related task performance by amyloid Abeta transgenic mice and by young and aged monkeys. Neuropharmacology 53: 588-600.
38. Buccafusco, J.J. 2004. Neuronal nicotinic receptor subtypes: defining therapeutic targets. Mol. Interv. 4: 285-295.
39. Luebke, J.I., Y.M. Chang, T.L. Moore & D.L. Rosene. 2004. Normal aging results in decreased synaptic excitation and increased synaptic inhibition of Layer 2/3 pyramidal cells in the monkey prefrontal cortex. Neuroscience 125: 277-288.
40. Masliah, E., A. Miller & R.D. Terry. 1993. The synaptic organization of the neocortex in Alzheimer's disease. Med. Hypotheses 41: 334-340.
41. Lu, T., Y. Pan, S.Y. Kao, et al. 2004. Gene regulation and DNA damage in the ageing human brain. Nature 429: 883-891.
42. Loerch, P.M., T. Lu, K.A. Dakin, et al. 2008. Evolution of the aging brain transcriptome and synaptic regulation. PLoS. One 3: e3329.
43. Gazzaley, A.,W. Clapp, J. Kelley, et al. 2008. Age-related top-down suppression deficit in the early stages of cortical visual memory processing. Proc. Natl. Acad. Sci. USA 105: 13122-13126.
44. Aisen, P.S. 2009. Alzheimer's disease therapeutic research: the path forward Alzheimers. Res. Ther. 1: 2.
45. Ferri, C.P., M. Prince, C. Brayne, et al. 2005. Global prevalence of dementia: aDelphi consensus study. Lancet 366: 2112-2117.
46. Plassman, B.L., K.M. Langa, G.G. Fisher, et al. 2007. Prevalence of dementia in the United States: the aging, demographics, and memory study. Neuroepidemiology 29: 125-132.
47. Morris, K. 2008. Experts urge smart thinking on cognitive enhancers. Lancet Neurol. 7: 476-477
48. Bailey, C.H., E.R. Kandel & K. Si. 2004. The persistence of long-term memory: a molecular approach to selfsustaining changes in learning-induced synaptic growth. Neuron 44: 49-57.
49. Bates, T.C., J.F. Price, S.E. Harris, et al. 2009. Association of KIBRA and memory. Neurosci. Lett. 458: 140-143.
50. Buther, K., C. Plaas, A. Barnekow & J. Kremerskothen. 2004. KIBRA is a novel substrate for protein kinase. Czeta Biochem. Biophys. Res. Commun. 317: 703-707.